Abstract
Abstract Background: Dupilumab is a completely human monoclonal antibody that blocks the shared receptor component for interleukin (IL)-4 and IL-13, which are important factors in type 2 inflammation in a variety of illnesses. In this case, dupilumab’s safety and effectiveness in treating moderate-to-severe uncontrolled asthma were examined by a systematic review and meta-analysis. Methods: We searched PubMed, Web of Science and Scopus from the beginning until April 2024 using the following search strategy: ‘Dupilumab’ AND ‘Asthma’ to find relevant publications that needed to be screened in order to be considered for inclusion in our study. Results: Dupilumab showed a statistically significant higher increase in forced expiratory volume 1 s (FEV1) after treatment compared to placebo with standardised mean difference (SMD) of 1.09 (95% confidence intervals [CI]: 0.41, 1.77, P = 0.002) and I 2 = 99%, P < 0.00001. Dupilumab showed a statistically significant decrease in the Asthma Control Questionnaire (ACQ) after treatment compared to placebo with SMD of − 5.22 (95% CI: −8.35, −2.1, P = 0.001) and I 2 = 100%, P < 0.00001. Dupilumab was associated with decreased exacerbation rate compared to placebo with odds ratio of 0.53 (95% CI: 0.29, 0.99, P = 0.04) and I 2 = 70%, P = 0.03. Conclusion: The current study provided a comprehensive overview of dupilumab’s efficacy in individuals with moderate-to-severe asthma when compared to a placebo by pooled analysis of randomised controlled trials. We demonstrated the great effectiveness of dupilumab in this patient group that had not responded to standard therapy, as seen by improvements in FEV1, ACQ and exacerbation rates.
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call